Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma

Blanchard, Gabriela; Guenova, Emmanuella

doi:10.1111/bjd.20821

Scientific article

Comment

English

Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma

ContributorsBlanchard, Gabriela

; Guenova, Emmanuella

Published inBritish journal of dermatology, vol. 186, no. 1, p. 15-16

Publication date2022-01

First online date2021-11-02

Abstract

Comment on : Trum NA, Zain J, Martinez XU, Parekh V, Afkhami M, Abdulla F, Carson KR, Rosen ST, Bennett CL, Querfeld C. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series. Br J Dermatol. 2022 Jan;186(1):153-166. doi: 10.1111/bjd.20708. Epub 2021 Oct 20. PMID: 34427917; PMCID: PMC8738116.

Keywords

Antibodies, Monoclonal, Humanized / adverse effects
Exanthema / chemically induced
Humans
Lymphoma
Skin Neoplasms / drug therapy

Affiliation entities

Not a UNIGE publication

Research groups

Inflammation cutanée (919)

Citation (ISO format)

BLANCHARD, Gabriela, GUENOVA, Emmanuella. Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma. In: British journal of dermatology, 2022, vol. 186, n° 1, p. 15–16. doi: 10.1111/bjd.20821

Article (Published version)

Identifiers

PID : unige:183658
DOI : 10.1111/bjd.20821
PMID : 34988981

Additional URL for this publicationhttps://academic.oup.com/bjd/article/186/1/15/6593538

Journal ISSN0007-0963

38views

0downloads

Creation17/02/2025 08:34:50

First validation05/03/2025 15:51:37

Update16/06/2026 12:29:23

Status update16/06/2026 12:29:23

Last indexation16/06/2026 12:29:23

Archive ouverte UNIGE

Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma

Technical informations